UB Paderborn / Katalog / Suche / in CDI

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

Journal of clinical oncology, 2015-01, Vol.33 (2), p.172-179

2015

Link zum Volltext

Verfügbarkeit prüfen

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

The New England journal of medicine, 2016-08, Vol.375 (5), p.422-434

2016

Link zum Volltext

Verfügbarkeit prüfen

Exposure-Response (Safety) Analysis to Identify Linifanib Dose for a Phase III Study in Patients With Hepatocellular Carcinoma

Clinical therapeutics, 2013-11, Vol.35 (11), p.1770-1777

2013

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Double-Blind Study of Fenofibric Acid Plus Rosuvastatin Compared With Rosuvastatin Alone in Stage 3 Chronic Kidney Disease

Clinical therapeutics, 2013-08, Vol.35 (8), p.1186-1198

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 trial of linifanib (ABT‐869) in patients with unresectable or metastatic hepatocellular carcinoma

Cancer, 2013-01, Vol.119 (2), p.380-387

2013

Link zum Volltext

Verfügbarkeit prüfen

Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST)

Arteriosclerosis, thrombosis, and vascular biology, 2014-06, Vol.34 (6), p.1298

2014

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer

Journal of clinical oncology, 2015-02, Vol.33 (5), p.433-441

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer

Journal of thoracic oncology, 2011-08, Vol.6 (8), p.1418-1425

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure

European journal of cancer (1990), 2011-12, Vol.47 (18), p.2706-2714

2011

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)

Cancer chemotherapy and pharmacology, 2014-07, Vol.74 (1), p.37-43

2014

Link zum Volltext

Verfügbarkeit prüfen

Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors

Cancer chemotherapy and pharmacology, 2014-01, Vol.73 (1), p.213-217

2014

Link zum Volltext

Verfügbarkeit prüfen

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors

Cancer chemotherapy and pharmacology, 2012-06, Vol.69 (6), p.1477-1486

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia

Leukemia & lymphoma, 2012-08, Vol.53 (8), p.1543-1551

2012

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer

Clinical colorectal cancer, 2014-09, Vol.13 (3), p.156-163.e2

2014

Link zum Volltext

Verfügbarkeit prüfen

Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial

Cardiovascular drugs and therapy, 2012-08, Vol.26 (4), p.349-358

2012

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia: A Randomized, Double-Blind Study

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010-01, Vol.10 (3), p.175-186

2010

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia – A Phase 3 Study

Cardiovascular drugs and therapy, 2010-12, Vol.24 (5-6), p.421-428

2010

Link zum Volltext

Verfügbarkeit prüfen

Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus

Cardiovascular drugs and therapy, 2011-02, Vol.25 (1), p.47-57

2011

Link zum Volltext

Verfügbarkeit prüfen

Combination Rosuvastatin Plus Fenofibric Acid in a Cohort of Patients 65 Years or Older With Mixed Dyslipidemia: Subanalysis of Two Randomized, Controlled Studies

Clinical cardiology (Mahwah, N.J.), 2010-10, Vol.33 (10), p.609-619

2010

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Fenofibric Acid + Rosuvastatin Versus Rosuvastatin Alone in Patients With Mixed Dyslipidemia and Stage 3 Chronic Kidney Disease

Journal of clinical lipidology, 2012-05, Vol.6 (3), p.269-270

2012

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Fixed-Dose Rosuvastatin/Fenofibric Acid Versus Simvastatin Monotherapy in Patients with Elevated Low-Density Lipoprotein Cholesterol and Triglycerides

Journal of clinical lipidology, 2010, Vol.4 (3), p.213-213

2010

Link zum Volltext

Verfügbarkeit prüfen

Simultaneous Achievement of Optimal Lipid Levels with the Combination of Fenofibric Acid and Rosuvastatin in Patients with Mixed Dyslipidemia

Journal of clinical lipidology, 2009, Vol.3 (3), p.214-215

2009

Link zum Volltext

Verfügbarkeit prüfen

Targeting the unmet medical need: the Abbott Laboratories oncology approach

Clinical advances in hematology & oncology, 2005-09, Vol.3 (9), p.703

2005

Link zum Volltext

Verfügbarkeit prüfen

205: ABT-335 in Combination with Rosuvastatin Improves Multiple Lipid Ratios in Patients with Mixed Dyslipidemia

Journal of clinical lipidology, 2008, Vol.2 (3), p.211-212

2008

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Fenofibric Acid and Rosuvastatin Combination Therapy in Women 55 Years or Older (Post-Menopausal) with Mixed Dyslipidemia

Journal of clinical lipidology, 2009, Vol.3 (3), p.221-222

2009

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Exposure-Response (Safety) Analysis to Identify Linifanib Dose for a Phase III Study in Patients With Hepatocellular Carcinoma

A Randomized, Double-Blind Study of Fenofibric Acid Plus Rosuvastatin Compared With Rosuvastatin Alone in Stage 3 Chronic Kidney Disease

Phase 2 trial of linifanib (ABT‐869) in patients with unresectable or metastatic hepatocellular carcinoma

Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST)

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer

Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure

A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)

Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors

Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia

Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer

Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial

Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia: A Randomized, Double-Blind Study

Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia – A Phase 3 Study

Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus

Combination Rosuvastatin Plus Fenofibric Acid in a Cohort of Patients 65 Years or Older With Mixed Dyslipidemia: Subanalysis of Two Randomized, Controlled Studies

Efficacy and Safety of Fenofibric Acid + Rosuvastatin Versus Rosuvastatin Alone in Patients With Mixed Dyslipidemia and Stage 3 Chronic Kidney Disease

Efficacy and Safety of Fixed-Dose Rosuvastatin/Fenofibric Acid Versus Simvastatin Monotherapy in Patients with Elevated Low-Density Lipoprotein Cholesterol and Triglycerides

Simultaneous Achievement of Optimal Lipid Levels with the Combination of Fenofibric Acid and Rosuvastatin in Patients with Mixed Dyslipidemia

Targeting the unmet medical need: the Abbott Laboratories oncology approach

205: ABT-335 in Combination with Rosuvastatin Improves Multiple Lipid Ratios in Patients with Mixed Dyslipidemia

Efficacy and Safety of Fenofibric Acid and Rosuvastatin Combination Therapy in Women 55 Years or Older (Post-Menopausal) with Mixed Dyslipidemia

Suchergebnisse filtern